Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
Novo Nordisk NVO has received another commercial boost as the Medicare GLP-1 Bridge program officially went live on July…
Novo Nordisk’s Stock Hinges on ADA Data as US Reimbursement Window Narrows
Novo Nordisk presents CagriSema and zenagamtide data at ADA, while CVS Caremark ends Wegovy’s exclusive formulary status, intensifying…
Novo Nordisk: Reimbursement Milestones and Pill Approval Signal New Growth Levers, But Stock Remains
Novo Nordisk secures French reimbursement and EU oral Wegovy nod, but shares plunge 35% as US competition and…
Novo Nordisk at a Crossroads: Reimbursement Milestones and Pipeline Data Collide with Pricing and Fo
Novo Nordisk stock claws back from March low but faces pricing pressure in North America, reimbursement wins in…
Novo Nordisk Navigates a Market Split: European Reimbursement Gains Offset by Generic Erosion in Eme
France to reimburse Wegovy from June, unlocking 1M patients, but generic Ozempic in Brazil, India, Canada erodes pricing…
Novo Nordisk Faces Swedish Reimbursement Challenge and Shifts US Legal Strategy
Novo Nordisk appeals Sweden’s Wegovy reimbursement denial, withdraws US patent lawsuit. Reports strong 2025 revenue growth but shares…
European Wegovy Dose Expansion Raises Fresh Questions For Novo Nordisk Valuation
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…